HomeCompareBIESF vs GBDC

BIESF vs GBDC: Dividend Comparison 2026

BIESF yields 0.15% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.77M in total portfolio value
10 years
BIESF
BIESF
● Live price
0.15%
Share price
$32.00
Annual div
$0.05
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$75.0K
Annual income
$32,334.90
Full BIESF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — BIESF vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIESFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIESF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIESF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIESF
Annual income on $10K today (after 15% tax)
$12.37/yr
After 10yr DRIP, annual income (after tax)
$27,484.67/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,955,639.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIESF + GBDC for your $10,000?

BIESF: 50%GBDC: 50%
100% GBDC50/50100% BIESF
Portfolio after 10yr
$10.46M
Annual income
$8,241,534.37/yr
Blended yield
78.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

BIESF
No analyst data
Altman Z
2.2
Piotroski
4/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIESF buys
0
GBDC buys
0
No recent congressional trades found for BIESF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIESFGBDC
Forward yield0.15%11.86%
Annual dividend / share$0.05$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%51.1%
Portfolio after 10y$75.0K$20.85M
Annual income after 10y$32,334.90$16,450,733.83
Total dividends collected$52.6K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: BIESF vs GBDC ($10,000, DRIP)

YearBIESF PortfolioBIESF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$10,729$29.12$12,492$1,791.70$1.8KGBDC
2$11,539$58.39$16,527$3,160.58$5.0KGBDC
3$12,464$117.38$23,588$5,904.90$11.1KGBDC
4$13,573$236.99$37,141$11,901.65$23.6KGBDC
5$15,006$482.41$66,205$26,463.38$51.2KGBDC
6$17,053$996.86$137,452$66,612.65$120.4KGBDC
7$20,364$2,117.50$342,372$195,298.53$322.0KGBDC
8$26,516$4,726.47$1,053,292$686,954.33$1.03MGBDC
9$39,876$11,503.41$4,111,439$2,984,416.95$4.07MGBDC
10$75,002$32,334.90$20,849,974$16,450,733.83$20.77MGBDC

BIESF vs GBDC: Complete Analysis 2026

BIESFStock

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Full BIESF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this BIESF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIESF vs SCHDBIESF vs JEPIBIESF vs OBIESF vs KOBIESF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.